Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...
Novartis and PTC Therapeutics are advancing their Huntington’s disease drug, votoplam, into a Phase 3 trial after mid-stage data showed it slowed disease progression by up to 52%. The move signals ...
However, that year marked the beginning of his journey with Huntington’s disease. “It’s not really, really obvious right now.
Stocktwits on MSN
QURE stock just shot up 8% - uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost
The boost comes after the U.S. Food and Drug Administration indicated in March that its trial data are not sufficient to support approval. ・The company will meet with the FDA in Q2 to discuss a ...
On April 28th 2026, PTC Therapeutics shared new data from the long-term extension of PIVOT-HD, the Phase 2 clinical trial of ...
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
TFC has been formally incorporated into the Unified Huntington’s Disease Rating Scale (UHDRS), which is the standard clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results